Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mass Spectrometry Software Integrated with Proteomics Data Analysis System

By LabMedica International staff writers
Posted on 14 Oct 2009
Geneva Bioinformatics, SA (GeneBio; Geneva, Switzerland) and Integromics S.L. More...
(Madrid, Spain) reported that GeneBio's Phenyx software platform for mass spectrometry (MS) data analysis has been successfully integrated into Integromics' latest proteomics data analysis and management tool--OmicsHub Proteomics. This integration gives Phenyx and OmicsHub Proteomics users the possibility of combining results from different search engines, thereby increasing the accuracy of the protein identification process.

OmicsHub Proteomics serve as an end-to-end proteomics data analysis and management system, from protein peak detection to generation of final reports. It has been developed in cooperation with ProteoRed, the Spanish National Proteomics Network (Madrid, Spain), ensuring in this way that the solution is close to the reality of a proteomics laboratory and that it helps to solve the most typical traffic jams of this field.

Developed in collaboration with the Swiss Institute of Bioinformatics (SIB; Lausanne, Switzerland), Phenyx is GeneBio's software platform for the identification, quantization, and characterization of proteins and peptides from mass spectrometry data. The Phenyx platform is specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment via a customizable architecture and a novel user-friendly interface.

"One of the biggest advantages of OmicsHub Proteomics is that we can have integrated in one single platform all the steps of an MS experiment thus reducing time and data management complexity,” said Dr. Juan Pablo Albar, general coordinator of ProteoRed. "As our feedback contributed from the early stages of its creation, OmicsHub Proteomics solves typical problems we find on a daily basis and makes life easier when performing tasks such as multiple search engine support, pathways integration or report generation for external customers. On the other hand, we are glad to see that commercial companies also include in their software functionality which helps laboratories to easily meet proteomics standards such as PRIDE [PRoteomics IDEntifications] or MIAPE [Minimum Information About a Proteomics]. Since Phenyx is widely used within our network due to its unique capabilities for protein identification, OmicsHub enables our members to take a greater advantage of a central solution like Phenyx.”

"We are pleased with the integration of Phenyx within OmicsHub Proteomics as this should open up Phenyx to a host of new users,” said Nasri Nahas, CEO of GeneBio. "The OmicsHub Proteomics platform answers proteomics researchers' needs for proteomics data automation and data management/analysis; combined with the outstanding performance of Phenyx, we envision a winning platform that will immediately bring great value to users and at the same time instantly expand the potential Phenyx user base. We are excited about the future possibilities of this relationship.”

"With OmicsHub Proteomics, Integromics has stepped into the proteomics field, and we view proteomics as an area where Integromics can leverage its expertise in the life sciences industry and add value. OmicsHub Proteomics has been designed to provide a custom proteomics solution and the integration of Phenyx will provide our end users added flexibility in the protein analysis process,” said Prof. Jose Maria Carazo, CSO of Integromics.

Both Integromics S.L. and GeneBio presented their technology at HUPO 2009 in Toronto, Canada, on September 26-30, 2009.

Geneva Bioinformatics is a leading bioinformatics company providing the life science community with software that bridges the gap between information gathering and knowledge generation. The company focuses on mass spectrometry characterization of proteins and small molecules as well as proteome imaging, offering clients and partners a high degree of specialization essential to their research.

Integromics develops information technology (IT) systems for Life Sciences (genomics and proteomics) in two strategic areas: data management/integration and intelligent data analysis. The company has developed a network of collaborations and partnerships with leading industry and academic organizations to provide complete technologic solutions that enable scientists to make new discoveries from their research data. Integromics operates globally in Asia Pacific, Europe, and the United States.

Related Links:

Geneva Bioinformatics
Integromics
ProteoRed
Swiss Institute of Bioinformatics



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.